Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Core Insights - Artelo Biosciences has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust to evaluate ART27.13 for glaucoma treatment, with first patient enrollment expected in Q2 2026 [2][6] Group 1: Study Overview - The study will assess the effects of ART27.13, a peripherally selective synthetic cannabinoid, on intraocular pressure in patients with glaucoma or ocular hypertension [2][4] - The study is titled "A Pilot, Randomized, Cross-Over Study to Determine the Effects of an Oral, Peripherally Selective, Synthetic Cannabinoid ART27.13 on Intraocular Pressure" and will be led by Professor Augusto Azuara-Blanco, a recognized authority in glaucoma management [5][6] Group 2: Funding and Support - The study is funded by Glaucoma UK and the HSC R&D Division, organizations dedicated to improving patient outcomes through innovative health research [2][3] - Artelo will supply ART27.13 capsules as the Investigational Medicinal Product for the study, which has received ethics committee approval [6] Group 3: Clinical Significance - Glaucoma affects over 80 million people globally and is a leading cause of irreversible blindness, with elevated intraocular pressure being a primary modifiable risk factor [3] - Existing glaucoma treatments often face challenges related to adherence and long-term efficacy, highlighting the need for new therapeutic options [3][7] Group 4: ART27.13 Profile - ART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist designed to selectively target peripheral CB1 and CB2 receptors, potentially improving intraocular pressure regulation [8][9] - The drug has shown a statistically significant and dose-dependent increase in body weight in clinical studies, indicating its potential beyond glaucoma treatment [9] Group 5: Strategic Implications - The collaboration with Belfast Health and Social Care Trust exemplifies Artelo's capital-efficient development strategy, leveraging investigator-initiated research to broaden the utility of ART27.13 while maintaining focus on its primary indication in cancer-related anorexia [7] - The study aims to provide insights into the safety and efficacy of ART27.13 in lowering intraocular pressure without psychotropic side effects, addressing a significant unmet need in glaucoma management [7]